Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study

Study Overview
=================
Brief Summary
-----------------
This is a prospective, observational, longitudinal study to assess clinical outcomes in the 12-months following participants' exit from protocol SBM-OWP-03, Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder (RESTORE; ClinicalTrials.gov Identifier: NCT05053503). Clinical outcome scores will be collected at study exit from protocol SBM-OWP-03, 1 month, 3 months, 6 months, 9 months, and 12 months after study exit from protocol SBM-OWP-03.

Official Title
-----------------
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study

Conditions
-----------------
Opioid Use Disorder, Relapse

Intervention / Treatment
-----------------
* Behavioral: Clinical Outcomes and Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consented participant for protocol SBM-OWP-03, Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder (RESTORE) Participant is English proficient Participant is able to provide informed consent and function at an intellectual level sufficient for study requirements Exclusion Criteria: Participant is unable to reliably receive and respond to assessments via email or telephone Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants randomized to receive tAN therapy in SBM-OWP-03 Phase II<br> | Behavioral: Clinical Outcomes and Questionnaires<br>* Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.<br>|
| Participants not randomized to receive tAN therapy in SBM-OWP-03 Phase II<br> | Behavioral: Clinical Outcomes and Questionnaires<br>* Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants in Phase II with a relapse event |  | 12 months (total duration of trial) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants in either Phase I or Phase II with a relapse event | Comparison of the proportion of participants in either Phase I or Phase II with a relapse event over the 12-month follow-up period | 12 months (total duration of trial) | 
| Mean change in recovery capital measured by Brief Assessment of Recovery Capital (BARC-10) | The BARC-10 is a short,10-item measure that examines recovery capital globally. Items were selected from the ARC for the BARC-10 using item response theory. The BARC-10 measures a unidimensional (i.e., global) construct of recovery capital across all the original 10 domains of the ARC. On average, it takes 2-5 minutes to complete. Scores range from 6-60. Individuals who have a recovery capital score of 47 or higher are likely to reach or sustain a year or longer of recovery from substance use disorder. | Baseline to Study Completion (12 months) | 
| Mean change in opioid craving measured by the Opioid Craving Scale (OCS) | Participants are asked to answer the following three questions with responses ranging from 0-10, where 0=Not at all and 10=Extremely. Total possible score ranges from 0-30 with greater scores indicating higher opioid craving: (1) How much do you currently crave opiates? (2) In the past week, please rate how strong your desire to use opiates has been when something in the environment has reminded you of opiates (example: seeing a medication bottle, using the Internet, visiting a doctor's office, going to a place where you used to buy drugs)? (3) Please imagine yourself in the environment in which you previously used opiates (examples: a party, a hangout, a particular room where you live). If you were in this environment today and if it were the time of day that you typically used opiates, what is the likelihood that you would use opiates today? | Baseline to Study Completion (12 months) | 
| Mean change in protracted withdrawal symptoms measured by the Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) | The SOWS-Gossop is an appropriate, precise, and sensitive measure to evaluate the symptoms of acute opioid withdrawal in research or clinical settings. The scale was derived from the original 32-item Opiate Withdrawal Scale to reduce redundancy while providing an equally sensitive measure of opioid withdrawal symptom severity appropriate for research and clinical practice. The assessment is a self-administered test used for the assessment of opiate withdrawal symptoms. The scale contains ten items: yawning, muscular tension, runny eyes, muscle twitching, pains, and aches, feeling of coldness, stomach cramps, insomnia, heart pounding, and feeling sick, making it easy and rapid to administer. The tool has a 4-point rating scale: 0 for 'none,' 1 for 'mild,' 2 for 'moderate,' and 3 for 'severe', with scores ranging from 0 to 30. | Baseline to Study Completion (12 months) | 
| Mean change in depression symptoms across time measured by Patient Health Questionnaire (PHQ-9) | The PHQ-9 is a validated tool in mental health and considered a powerful tool to assist clinicians with diagnosing depression and monitoring treatment response. The relationship between opioid use and depression is bidirectional. The PHQ-9 is a nine-item depression scale and is based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV. Each of the nine items is rated on a 0 (not at all) to 3 (nearly every day) scale. A total score is calculated by summing the nine items. Scores range from 0 to 27 and higher scores indicate a higher degree of depression. | Baseline to Study Completion (12 months) | 
| Mean change in anxiety across time measured by Generalized Anxiety Disorder (GAD-7) | The GAD-7 is a valid and efficient tool for screening for GAD and assessing its severity in clinical practice and research. The questionnaire consists of 7 questions in which participants are asked to rate each item on a 0 (not at all) to 3 (nearly every day). GAD-7 total score for the seven items ranges from 0 to 21 where 0-4 represents minimal anxiety, 5-9 represents mild anxiety, 10-14 represents moderate anxiety and 15-21 represent severe anxiety. | Baseline to Study Completion (12 months) | 
| Mean change in PTSD symptoms across time measured by the PTSD Checklist for DSM-5 (PCL-5) | Symptoms of post-traumatic stress disorder (PTSD) and opiate dependency may overlap, to which, opioid withdrawal symptoms may emulate PTSD hyperactive startle response. This is indicative a common physiological mechanism. The PCL-5 scale is the gold standard in PTSD assessment. It consisted of a 20-item self-report measurement that is capable of measuring symptom change during and after treatment. Additionally, the scale can provide a provisional PTSD diagnosis. Each of the 20 items is rated on a 0 (not at all) to 4 (extremely) scale. A total symptom severity score is calculated by summing the 20 items. Scores range from 0 and 80 and higher scores indicating a higher degree of PTSD symptomology. Evidence suggests that a10 to 20-point reduction in score represents a clinically significant change in PTSD symptoms. | Baseline to Study Completion (12 months) | 
| Mean change in Quality of Life across time measured by World Health Organization Quality of Life(WHOQOL-BREF) domain scores | The WHOQOL-BREF is a shorter version of the original assessment tool and is commonly used in clinical trials with participants undergoing substance use disorder intervention. The WHOQOL-BREF is comprised of 26-items and assesses the participant's quality of life across specific domains: physical health, psychological health, social relationships, and environment.24 In addition, there are 2 items that measure overall quality of life and general health. Participants rate how much they have experienced each item in the preceding two weeks on a 5-point Likert scale ranging from 1 (not at all) to 5 (completely). Domain scores are scaled in a positive direction with higher scores denoting higher quality of life. The mean score of items within each domain is used to calculate the domain score. Raw domain scores will be converted to a 0 to 100 scale. | Baseline to Study Completion (12 months) | 
| Mean change in Commitment to Sobriety Scale (CSS-5) | Ratings of participant-perceived level of motivation and dedication to achieving initial and maintaining on-going sobriety for substance use will be measured using the 5-item Commitment to Sobriety Scale (CSS-5). Each statement is rated on a 6-point Likert scale, ranging from 1 (strongly disagree) to 6 (strongly agree). Example items include: Staying sober is the most important thing in my life and I will do whatever it takes to recover from my addiction. Following the completion of the CSS-5, participants will be asked to reflect and rate level of confidence on their commitment to abstinence for the next 30 days using a 10-point scale, from 1 (not at all confident) to 10, (very confident). | Baseline to Study Completion (12 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
relapse prevention